We are live on ! Find out more
ENTX icon

Entera Bio

5 hedge funds and large institutions have $2.01M invested in Entera Bio in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 55 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.26% less ownership

Funds ownership: 10.45%10.19% (-0.26%)

15% less capital invested

Capital invested by funds: $2.36M → $2.01M (-$355K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
1
Knoll Capital Management
Florida
$1.88M
Renaissance Technologies
2
Renaissance Technologies
New York
$78K +$79.8K +72,186 New
VF
3
Virtu Financial
New York
$34K +$34.6K +31,314 New
PF
4
Phoenix Financial
Israel
$14K
UBS Group
5
UBS Group
Switzerland
$1K -$8.14K -7,368 -94%
WS
6
Wedbush Securities
California
-$151K -121,616 Closed
Citadel Advisors
7
Citadel Advisors
Florida
-$28K -22,020 Closed

ENTX Hedge Fund Activity: Q4 2020 in Review

5 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2020, worth a combined $2.01M — down 15% from $2.36M a quarter earlier.

Fund positioning in ENTX was balanced in Q4 2020: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $79.8K. The largest seller was Wedbush Securities, exiting entirely with an estimated $151K sold.

  • 5 institutional investors held Entera Bio (ENTX) as of Q4 2020, unchanged from Q3 2020.
  • Funds reported $2.01M of Entera Bio stock for Q4 2020, down 15% quarter-over-quarter.
  • 2 funds opened new Entera Bio positions in Q4 2020 and 2 closed out, a net change of 0 holders.
  • The largest Entera Bio buyer in Q4 2020 was Renaissance Technologies, an estimated $79.8K added.
  • The largest Entera Bio seller in Q4 2020 was Wedbush Securities, an estimated $151K sold.

Based on aggregated 13F filings for Q4 2020.